Factor XIII Deficiency: Laboratory, Molecular, and Clinical Aspects
Authors:
- 29 November 2024
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 51 (02) , 155-169
Abstract
Factor XIII-A (FXIII-A) deficiency is an ultra-rare bleeding disorder characterized by high rates of morbidity and mortality, primarily resulting from intracranial hemorrhage, umbilical cord bleeding, and miscarriage, whereas patients with severe FXIII-B deficiency present with a milder phenotype. Although the estimated incidence of severe FXIII-A deficiency is one per 2 million, a high prevalence ranging from 0.8 to 3.5% has been observed for heterozygous FXIII-A deficiency. Unlike most bleeding disorders, individuals with heterozygous FXIII-A deficiency, particularly women, are more likely to experience hemorrhagic complications during hemostatic challenges. About 200 Mutations have been observed in F13A and F13B genes, with most being missense mutations, while large deletions are the rarest. There is no correlation between genotype and phenotype and a moderate to strong correlation between factor activity and clinical severity in FXIII-A deficiency, making it difficult to predict bleeding patterns based on genotype and FXIII activity levels. Primary prophylaxis is mandatory for all patients with severe FXIII-A deficiency, while those with heterozygous deficiency are generally asymptomatic and may require on-demand therapy during hemostatic challenges, most commonly in women. On the other hand, patients with severe FXIII-B deficiency may only require on-demand therapy, while heterozygotes are generally asymptomatic. Although there are general recommended therapeutic regimens for prophylaxis or on-demand therapy in different situations, personalized pharmacokinetic-based replacement therapy represents the optimal approach that can optimize intervention efficacy. In such an approach, several factors may affect the effectiveness of treatment and determine the dose and type of intervention, including the classification of FXIII deficiency, residual plasma levels of FXIII, clinical situation requiring intervention, age, weight, and also gender.Keywords
This publication has 89 references indexed in Scilit:
- Congenital Bleeding Disorders: Diagnosis and Management2023
- The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparisonJournal of Thrombosis and Thrombolysis, 2022
- The impact of antenatal factor XIII levels on postpartum haemorrhage: a prospective observational studyArchives of Gynecology and Obstetrics, 2018
- Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiencyAnnals of Hematology, 2015
- Factor XIII deficiency and head trauma: management and therapyNeurological Sciences, 2015
- Causes and timing of delayed bleeding after oral surgeryClinical Oral Investigations, 2013
- Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection controlInternational Journal of Hematology, 2012
- Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effectAnnals of Hematology, 2009
- Deficiency of Factor XIII Gene in Chinese: 3 Novel MutationsInternational Journal of Hematology, 2003
- The fibrin stabilizing factor, factor XIIIAnnals of Hematology, 1973